Waypoint Capital
Waypoint Capital is a Geneva-based private investment firm (founded 2011) operating within the B-FLEXION group, investing in healthcare and specialty-services platforms including Stallergenes Greer and Allergy Partners.
- Company typePrivate
- Founded2011
- HeadquartersGenève, Switzerland
- Headcount51–100
- GTM typeB2B
- OfferingServices
What Waypoint Capital does
Waypoint Capital is a Geneva-based private investment firm founded in 2011 and operating as part of the B-FLEXION group, the entrepreneurial investment vehicle associated with the Bertarelli family. The firm invests across healthcare and specialty services, with a concentrated portfolio of majority-owned operating platforms including Stallergenes Greer, a global allergen immunotherapy company acquired in March 2019 for approximately $830 million, and Allergy Partners, a US allergy and immunology services business in which Waypoint acquired a majority stake in December 2021. In March 2026, Waypoint divested a majority stake in DME Express, a durable medical equipment provider serving hospices across nine US states with over 70 warehouse locations, to Palladium Equity Partners while retaining a minority interest.
Waypoint operates with a lean team of 51-100 employees headquartered in Geneva and a US operational presence (including a Head of Accounting and Operations, US). Leadership comprises Managing Partner Chris Viehbacher, CFO Gordon McNair, and US operations lead Gretchen McCarey. The firm's revenue mechanics derive from operating performance across its portfolio companies, realized investment gains, and management activity rather than disclosed third-party LP fee streams; consolidated financial figures are not publicly disclosed.
As a family-affiliated investment platform inside the broader B-FLEXION group, Waypoint's business model combines long-hold control investments, sector specialization in respiratory/allergy and hospice-adjacent services, and selective capital recycling through partial divestitures. There is no disclosed technology platform, product offering, or AI capability in the source material; the firm's competitive position rests on capital base, sector relationships, and operating oversight of a small number of healthcare assets.
Waypoint Capital firmographics
Firmographics- Name
- Waypoint Capital
- Website
- https://waypointcapital.net
- Company type
- Private
- Founded year
- 2011
- Headcount range
- 51–100 employees
- Short description
- Waypoint Capital is a Geneva-based private investment firm (founded 2011) operating within the B-FLEXION group, investing in healthcare and specialty-services platforms including Stallergenes Greer and Allergy Partners.
- Ownership category
- akta.pro rank
Waypoint Capital industry classification
Industry- Product category
- Private Equity & Investment Management
- NAICS
- Portfolio Management and Investment Advice (52394), Portfolio Management and Investment Advice (523940), Other Financial Investment Activities (5239)
- SIC
- Investment Advice (6282), Investors, Nec (6799)
- akta.pro primary industry
- Private Banking & UHNW Wealth Advisory (FSAEABAC)
- akta.pro secondary industries
- Thematic / Sector-Focused Multi-Manager Platforms (FSANAGAH), Private Equity Buyout Fund-of-Funds (FSANAGAD)
Keywords
Where Waypoint Capital is headquartered
LocationHeadquarters
- HQ city
- Genève
- HQ country
- Switzerland
- HQ region
- Europe
Markets served
Waypoint Capital business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Operations, Others, Technology or R&D
Waypoint Capital product offering
Product offeringCore offering
Waypoint Capital is a private investment firm that deploys capital — primarily associated with the Bertarelli family — into controlling equity stakes in operating businesses, with a focus on healthcare services, specialty pharmaceuticals, and life sciences. Its core activity is acquiring, holding, and managing portfolio companies (such as Allergy Partners and Stallergenes Greer), and realizing returns through divestitures, minority-stake retentions, and ongoing operating company management. The firm functions as the principal investment vehicle within the B-FLEXION group of asset managers.
Product overview
Waypoint Capital is a private equity investment firm that operates as a single unified investment platform. The firm focuses on acquiring and managing portfolio companies across healthcare and other sectors. Key holdings include Allergy Partners (majority stake acquired in 2021), a healthcare services company in the allergy and immunology space, and DME Express (majority stake sold to Palladium Equity Partners in 2026), a durable medical equipment provider serving hospice providers. The company is associated with the B-FLEXION investment group, which encompasses various asset managers and operating businesses including Kedge Capital, CrossTree Real Estate, Roxbury, Forestay Capital, Capital Four, Longview Partners, Twelve Securis, Forge Life Sciences Partners, and Stallergenes Greer.
Differentiator
Problem solved
Functional benefit
Products and services
- Allergy Partners
- DME Express
- Stallergenes Greer
Companies that use Waypoint Capital
Customer profileIdeal customer profiles1 record
Waypoint Capital technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Waypoint Capital partnerships and signals
Strategic signalRecent moves4 records
Expansion highlights4 records
Waypoint Capital competitors and assessment
Company assessmentBroad incumbents
- Bain Capital: Global multi-strategy private equity platform with dedicated healthcare, life sciences, and special situations funds. Overlaps with Waypoint's PE buyout activity but operates at vastly larger scale and broader sector coverage.
- CVC Capital Partners: Major European-rooted private equity firm running multi-billion-euro buyout funds with active healthcare exposure. Comparable to Waypoint in European orientation and Private Banking/UHNW-style client base, but orders of magnitude larger in AUM and headcount.
- Carlyle Group: Global alternative asset manager with dedicated healthcare and global private equity strategies. Operates at multibillion-dollar fund scale; comparable only in healthcare PE thesis, not in family-office origin or check size.
- TPG: Major alternative asset manager with TPG Capital and TPG Growth covering buyouts, growth, and healthcare (TPG Rise). Comparable in healthcare-services and life-sciences investing but institutional, not family-office, in capital structure.
- Investcorp: Global alternative investment firm with private equity, real estate, and credit strategies; strong foothold across Europe and the Middle East with growing US healthcare exposure. Structurally a comparable cross-Atlantic mid-market PE/family-office-adjacent platform.
- Hellman & Friedman: Large-cap private equity firm with significant healthcare services and life sciences investing (e.g., Multiplan, IRI). Comparable in life-sciences / healthcare services focus to Waypoint but with much larger average check sizes and broader portfolio diversification.
Emerging players
- Kainos Capital: Middle-market private equity firm focused on consumer and healthcare services. Overlaps with Waypoint in healthcare-services thesis (e.g., Allergy Partners) though smaller in scale and narrower in sector breadth.
Direct peers
- Patient Square Capital: Healthcare-focused private equity firm taking control and growth positions in healthcare services, medical devices, and life sciences — the same thesis Waypoint is executing through Allergy Partners, DME Express, Stallergenes Greer, and Forge Life Sciences Partners.
- Pritzker Private Capital: Single-family private equity firm originating from the Pritzker family office, building middle-market operating businesses across healthcare, industrial, and consumer — the closest structural analog to Waypoint within the B-FLEXION/Bertarelli family platform.
- Stone Point Capital: Family-influenced, multi-generational private equity firm with significant healthcare services and financial services exposure. Comparable in operating style to Waypoint's patient, family-backed model and its services-and-specialty healthcare focus.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks5 records
Key highlights5 records
Customer concentration
Waypoint Capital social profiles
Digital presenceWaypoint Capital financial estimates
Financial estimateRevenue estimate
Valuation estimate
Waypoint Capital leadership team
Management profileNumber of profiles
Profiles3 records
Waypoint Capital subsidiaries and ownership
Company hierarchySubsidiaries2 records
Waypoint Capital funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Waypoint Capital M&A and investment
M&A and investmentM&A2 records
Investments7 records
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Waypoint Capital
What does Waypoint Capital do?
Waypoint Capital is a private investment firm that deploys capital — primarily associated with the Bertarelli family — into controlling equity stakes in operating businesses, with a focus on healthcare services, specialty pharmaceuticals, and life sciences. Its core activity is acquiring, holding, and managing portfolio companies (such as Allergy Partners and Stallergenes Greer), and realizing returns through divestitures, minority-stake retentions, and ongoing operating company management. The firm functions as the principal investment vehicle within the B-FLEXION group of asset managers.
When was Waypoint Capital founded?
Waypoint Capital was founded in 2011. It employs 51 to 100 people.
Where is Waypoint Capital based?
Waypoint Capital is headquartered in Genève, Switzerland, in the Europe region.
Who are Waypoint Capital's main competitors?
Broad incumbents on record are Bain Capital, CVC Capital Partners, Carlyle Group, TPG, Investcorp and Hellman & Friedman. Kainos Capital is listed as an emerging player. Direct peers are Patient Square Capital, Pritzker Private Capital and Stone Point Capital.
Does Waypoint Capital have an API?
No public API is recorded for Waypoint Capital.
What industry is Waypoint Capital in?
Waypoint Capital's product category is Private Equity & Investment Management. Its primary akta.pro industry code is FSAEABAC, Private Banking & UHNW Wealth Advisory, with a secondary code of FSANAGAH, Thematic / Sector-Focused Multi-Manager Platforms. Its NAICS code is 52394 and its SIC code is 6282.